A detailed history of Great West Life Assurance CO transactions in Sage Therapeutics, Inc. stock. As of the latest transaction made, Great West Life Assurance CO holds 4,789 shares of SAGE stock, worth $23,226. This represents 0.0% of its overall portfolio holdings.

Number of Shares
4,789
Previous 4,789 -0.0%
Holding current value
$23,226
Previous $52,000 32.69%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 14, 2023

BUY
$16.75 - $48.98 $46,900 - $137,144
2,800 Added 140.77%
4,789 $99,000
Q2 2023

Aug 10, 2023

SELL
$40.65 - $59.54 $20,975 - $30,722
-516 Reduced 20.6%
1,989 $94,000
Q3 2022

Nov 01, 2022

BUY
$32.28 - $43.27 $80,861 - $108,391
2,505 New
2,505 $98,000
Q1 2022

May 12, 2022

SELL
$30.71 - $45.71 $15,109 - $22,489
-492 Reduced 16.42%
2,505 $88,000
Q2 2021

Aug 11, 2021

SELL
$54.88 - $79.29 $25,025 - $36,156
-456 Reduced 13.21%
2,997 $170,000
Q3 2020

Nov 17, 2020

BUY
$41.13 - $62.45 $20,318 - $30,850
494 Added 16.69%
3,453 $211,000
Q3 2020

Nov 13, 2020

SELL
$41.13 - $62.45 $20,318 - $30,850
-494 Reduced 14.31%
2,959 $180,000
Q4 2019

Feb 11, 2020

BUY
$60.18 - $154.77 $207,801 - $534,420
3,453 New
3,453 $249,000
Q3 2019

Oct 25, 2019

SELL
$140.29 - $189.96 $863,625 - $1.17 Million
-6,156 Closed
0 $0
Q2 2019

Jul 31, 2019

SELL
$157.85 - $183.09 $14,995 - $17,393
-95 Reduced 1.52%
6,156 $0
Q1 2019

May 08, 2019

BUY
$89.33 - $163.65 $51,275 - $93,935
574 Added 10.11%
6,251 $991,000
Q4 2018

Feb 12, 2019

BUY
$81.94 - $139.71 $40,232 - $68,597
491 Added 9.47%
5,677 $525,000
Q1 2018

May 10, 2018

BUY
$152.15 - $192.33 $155,801 - $196,945
1,024 Added 24.6%
5,186 $837,000
Q3 2017

Nov 09, 2017

BUY
$61.4 - $88.52 $255,546 - $368,420
4,162
4,162 $261,000

Others Institutions Holding SAGE

About Sage Therapeutics, Inc.


  • Ticker SAGE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,422,300
  • Market Cap $288M
  • Description
  • Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...
More about SAGE
Track This Portfolio

Track Great West Life Assurance CO Portfolio

Follow Great West Life Assurance CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Great West Life Assurance CO , based on Form 13F filings with the SEC.

News

Stay updated on Great West Life Assurance CO with notifications on news.